-
公开(公告)号：US09696312B2
公开(公告)日：2017-07-04
申请号：US14342440
申请日：2012-09-04
IPC分类号： A61K47/48 , G01N33/574 , C07K16/28 , C07K14/705
CPC分类号： G01N33/57492 , A61K47/6801 , A61K47/6803 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K14/7051 , C07K16/28 , C07K16/2803 , C07K16/3061 , C07K2319/30 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C07K2319/74 , G01N33/57426 , G01N33/57484 , G01N2333/70503 , G01N2333/70596 , G01N2458/00 , G01N2800/52
摘要： The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.
-
公开(公告)号：US20170327591A1
公开(公告)日：2017-11-16
申请号：US15609808
申请日：2017-05-31
IPC分类号： C07K16/30 , A61K47/68 , G01N33/574 , C07K16/28 , C07K14/725 , A61K39/00
摘要： The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.
-
公开(公告)号：US20150110714A1
公开(公告)日：2015-04-23
申请号：US14342440
申请日：2012-09-04
IPC分类号： G01N33/574 , C07K14/705 , C07K16/28
CPC分类号： G01N33/57492 , A61K47/6801 , A61K47/6803 , A61K47/6849 , A61K47/6867 , A61K2039/505 , C07K14/705 , C07K14/70503 , C07K14/7051 , C07K16/28 , C07K16/2803 , C07K16/3061 , C07K2319/30 , C07K2319/33 , C07K2319/40 , C07K2319/55 , C07K2319/74 , G01N33/57426 , G01N33/57484 , G01N2333/70503 , G01N2333/70596 , G01N2458/00 , G01N2800/52
摘要： The present invention relates to methods of using the expression of ILTL3 ligand or ILT3 on certain types of cancer cells as a diagnostic tool. Methods are provided for treating ILT3-ligand expressing cancers, such as T-cell acute lymphoblastic leukemia (T-cell acute lymphoblastic leukemia), for example by administering ILT3, the extracellular domain of ILT3 or ILT3Fc conjugated to a cytotoxic agent to kill the targeted cancer cell. Other methods are provided for treating cancers that express ILT3 on their surface, such as monocytic forms of AML, for example by administering anti-ILT3 antibodies conjugated to a cytotoxic agent.
摘要翻译： 本发明涉及使用ILTL3配体或ILT3表达的某些类型的癌细胞作为诊断工具的方法。 提供了用于治疗ILT3-配体表达癌症的方法，例如T细胞急性成淋巴细胞白血病（T细胞急性成淋巴细胞白血病），例如通过施用ILT3，与细胞毒性剂缀合的ILT3或ILT3Fc的细胞外结构域来杀死靶向 癌细胞。 提供其他方法用于治疗在其表面上表达ILT3的癌症，例如单克隆形式的AML，例如通过施用与细胞毒性剂缀合的抗ILT3抗体。
-
公开(公告)号：US08207110B2
公开(公告)日：2012-06-26
申请号：US11661877
申请日：2005-09-01
IPC分类号： A61K38/00
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译： 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中 该多肽是水溶性的。 本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。
-
公开(公告)号：US20090202544A1
公开(公告)日：2009-08-13
申请号：US12223496
申请日：2007-02-02
IPC分类号： A61K39/395 , A61K35/14 , C12Q1/68 , A61K31/7088 , C07H21/04
CPC分类号： C07K16/2803 , A61K35/14 , C07K14/70503 , C07K2319/30 , G01N33/57488
摘要： This invention provides a method of treating a subject afflicted with a disease, comprising withdrawing blood from the subject, treating the withdrawn blood so as to remove sILT3 from the blood, and returning the treated blood to the subject, thereby treating the subject afflicted with the disease. This invention also provides the above method, further comprising administering an anti-ILT3 antibody to the subject. The invention also provides a method of treating a subject afflicted with a disease, comprising administering to the subject an anti-ILT3 antibody, thereby treating the subject. In one embodiment, the disease is chronic viral disease. In another embodiment, the disease is cancer.
摘要翻译： 本发明提供一种治疗患有疾病的受试者的方法，包括从受试者中取出血液，处理所抽取的血液，以从血液中除去sILT3，并将经处理的血液返回给受试者，由此治疗患有 疾病。 本发明还提供了上述方法，其还包括对受试者施用抗ILT3抗体。 本发明还提供了治疗患有疾病的受试者的方法，其包括向受试者施用抗ILT3抗体，从而治疗受试者。 在一个实施方案中，该疾病是慢性病毒性疾病。 在另一个实施方案中，该疾病是癌症。
-
公开(公告)号：US20120321623A1
公开(公告)日：2012-12-20
申请号：US13480421
申请日：2012-05-24
IPC分类号： A61K38/17 , C07K19/00 , C12N5/0783 , A61P37/06 , A61K39/395
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译： 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中 该多肽是水溶性的。 本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。
-
公开(公告)号：US20080311073A1
公开(公告)日：2008-12-18
申请号：US11661877
申请日：2005-09-01
IPC分类号： A61K45/00 , C07K14/00 , C12N15/11 , C12N15/00 , A61P37/00 , A61K35/12 , C12N5/06 , C12P21/04
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译： 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中 该多肽是水溶性的。 本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。
-
公开(公告)号：US10765742B2
公开(公告)日：2020-09-08
申请号：US15745582
申请日：2016-07-18
申请人： Nicole Suciu-Foca , George Vlad , Zheng Xu
发明人： Nicole Suciu-Foca , George Vlad , Zheng Xu
IPC分类号： A61K39/00 , A61K39/395 , C07K16/28 , G01N33/574 , A61K38/17 , A61P35/00
摘要： It has now been discovered that activated lymphocyte cell adhesion molecule (ALCAM)—also known as CD166—is the ligand of the innate immune receptor ILT3 that is expressed by DC and monocytes. It has been further discovered that the specific binding of ILT3 to its ligand CD166 on the surface of CD166-expressing cancer cells, arrested cancer cell growth and initiated apoptosis. Therefore, certain embodiments relate to methods and compositions for treating CD166-expressing cancers by administering ILT3Fc, full-length ILT3 or any CD166 ligand-binding fragment thereof.
-
公开(公告)号：US20160152682A1
公开(公告)日：2016-06-02
申请号：US14733432
申请日：2015-06-08
IPC分类号： C07K14/705 , A61K38/17 , A61K45/06
CPC分类号： C07K14/70503 , A61K38/1774 , A61K39/001 , A61K45/06 , C07K2319/30
摘要： This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
-
公开(公告)号：US09150635B2
公开(公告)日：2015-10-06
申请号：US13480421
申请日：2012-05-24
IPC分类号： A61K38/16 , C07K14/705
CPC分类号： C07K14/70503 , C07K2319/30
摘要： This invention provides a first polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water-soluble and does not comprise the Fc portion of an immunoglobulin. This invention also provides a second polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) the Fc portion of an immunoglobulin, wherein the Fc portion of the immunoglobulin comprises a function-enhancing mutation, and wherein the polypeptide is water-soluble. This invention further provides a third polypeptide comprising (i) all or a portion of the extracellular domain of ILT3 operable affixed to (ii) a transmembrane domain. This invention further provides related nucleic acids, expression vectors, host vector systems, compositions, and articles of manufacture and therapeutic and prophylactic methods using the polypeptides of the invention.
摘要翻译： 本发明提供了包含ILT3的全部或部分细胞外结构域的第一多肽，其中多肽是水溶性的并且不包含免疫球蛋白的Fc部分。 本发明还提供了第二多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地附着于（ii）免疫球蛋白的Fc部分，其中所述免疫球蛋白的Fc部分包含功能增强突变，并且其中 该多肽是水溶性的。 本发明还提供了第三多肽，其包含（i）ILT3的全部或部分细胞外结构域可操作地固定于（ii）跨膜结构域。 本发明还提供了使用本发明的多肽的相关核酸，表达载体，宿主载体系统，组合物和制品以及治疗和预防方法。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.029 秒)
